b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="In-Process" Owner="NLM">\n        <PMID Version="1">32162383</PMID>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>05</Month>\n            <Day>04</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1346-8138</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>47</Volume>\n                    <Issue>5</Issue>\n                    <PubDate>\n                        <Year>2020</Year>\n                        <Month>May</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>The Journal of dermatology</Title>\n                <ISOAbbreviation>J. Dermatol.</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Downregulation of lysyl oxidase in venous malformations: Association with vascular destabilization and sclerotherapy.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>518-526</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1111/1346-8138.15297</ELocationID>\n            <Abstract>\n                <AbstractText>Venous malformations (VM) are localized defects in vascular morphogenesis manifested by dilated venous channels with reduced perivascular cell coverage. As a vital enzyme for extracellular matrix (ECM) deposition, lysyl oxidase (LOX) plays important roles in vascular development and diseases. However, the expression and significance of LOX are unknown in VM. Herein, 22 VM specimens and eight samples of normal skin tissues were evaluated immunohistochemically for the expression of LOX, \xce\xb1-smooth muscle cell actin (\xce\xb1-SMA) and transforming growth factor-\xce\xb2 (TGF-\xce\xb2). In vitro studies on human umbilical vein endothelial cells (HUVEC) were employed for determining potential mechanisms. Our results showed that LOX expression was significantly reduced in VM compared with normal skin tissues, in parallel with attenuated perivascular \xce\xb1-SMA<sup>+</sup> cell coverage and TGF-\xce\xb2 downregulation in VM. Further correlation analysis indicated that LOX expression was positively correlated with perivascular \xce\xb1-SMA<sup>+</sup> cell coverage and TGF-\xce\xb2 expression in VM. Moreover, marked elevation of LOX, TGF-\xce\xb2 and \xce\xb1-SMA was observed in bleomycin-treated VM samples. Furthermore, our in vitro data demonstrated that both recombinant TGF-\xce\xb2 and bleomycin induced obvious increase of LOX expression and activity and a concomitant increase in ECM components in HUVEC, which could be reversed by LOX inhibition. To our best knowledge, this study revealed for the first time the downregulation of LOX in VM and its correlation with vascular destabilization and TGF-\xce\xb2-induced endothelial ECM deposition. Moreover, our results highlighted that LOX may be implicated in the sclerotherapy of VM and holds promise as a therapeutic target.</AbstractText>\n                <CopyrightInformation>\xc2\xa9 2020 Japanese Dermatological Association.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Zhu</LastName>\n                    <ForeName>Junyi</ForeName>\n                    <Initials>J</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Stomatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Shao</LastName>\n                    <ForeName>Ming</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Stomatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Guo</LastName>\n                    <ForeName>Fengyuan</ForeName>\n                    <Initials>F</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Stomatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Ren</LastName>\n                    <ForeName>Jiangang</ForeName>\n                    <Initials>J</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Oral and Maxillofacial Surgery, School and Hospital of Stomatology, Wuhan University, Wuhan, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Tang</LastName>\n                    <ForeName>Zirong</ForeName>\n                    <Initials>Z</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Stomatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Geng</LastName>\n                    <ForeName>Jinhuan</ForeName>\n                    <Initials>J</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Stomatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Xu</LastName>\n                    <ForeName>Zhi</ForeName>\n                    <Initials>Z</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Stomatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Jia</LastName>\n                    <ForeName>Jun</ForeName>\n                    <Initials>J</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Oral and Maxillofacial Surgery, School and Hospital of Stomatology, Wuhan University, Wuhan, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Chen</LastName>\n                    <ForeName>Lili</ForeName>\n                    <Initials>L</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Stomatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Jia</LastName>\n                    <ForeName>Yulin</ForeName>\n                    <Initials>Y</Initials>\n                    <Identifier Source="ORCID">https://orcid.org/0000-0002-1000-1117</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Stomatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <GrantList CompleteYN="Y">\n                <Grant>\n                    <GrantID>81803113</GrantID>\n                    <Agency>National Natural Science Foundation of China</Agency>\n                    <Country/>\n                </Grant>\n                <Grant>\n                    <GrantID>81600385</GrantID>\n                    <Agency>National Natural Science Foundation of China</Agency>\n                    <Country/>\n                </Grant>\n                <Grant>\n                    <GrantID>2018CFB201</GrantID>\n                    <Agency>Natural Science Foundation of Hubei Province</Agency>\n                    <Country/>\n                </Grant>\n                <Grant>\n                    <GrantID>2019CFB716</GrantID>\n                    <Agency>Natural Science Foundation of Hubei Province</Agency>\n                    <Country/>\n                </Grant>\n                <Grant>\n                    <GrantID>02.03.2018-81</GrantID>\n                    <Agency>Key Laboratory Fund of Wuhan Union Hospital</Agency>\n                    <Country/>\n                </Grant>\n                <Grant>\n                    <GrantID>02.03.2017-42</GrantID>\n                    <Agency>Free Innovation Fund of Wuhan Union Hospital</Agency>\n                    <Country/>\n                </Grant>\n                <Grant>\n                    <GrantID>201906165065</GrantID>\n                    <Agency>China Scholarship Council (CSC)</Agency>\n                    <Country/>\n                </Grant>\n            </GrantList>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2020</Year>\n                <Month>03</Month>\n                <Day>11</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>England</Country>\n            <MedlineTA>J Dermatol</MedlineTA>\n            <NlmUniqueID>7600545</NlmUniqueID>\n            <ISSNLinking>0385-2407</ISSNLinking>\n        </MedlineJournalInfo>\n        <CitationSubset>IM</CitationSubset>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">bleomycin</Keyword>\n            <Keyword MajorTopicYN="N">lysyl oxidase</Keyword>\n            <Keyword MajorTopicYN="N">transforming growth factor-\xce\xb2</Keyword>\n            <Keyword MajorTopicYN="N">vascular destabilization</Keyword>\n            <Keyword MajorTopicYN="N">venous malformations</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2019</Year>\n                <Month>12</Month>\n                <Day>08</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2020</Year>\n                <Month>02</Month>\n                <Day>09</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2020</Year>\n                <Month>3</Month>\n                <Day>13</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2020</Year>\n                <Month>3</Month>\n                <Day>13</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2020</Year>\n                <Month>3</Month>\n                <Day>13</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">32162383</ArticleId>\n            <ArticleId IdType="doi">10.1111/1346-8138.15297</ArticleId>\n        </ArticleIdList>\n        <ReferenceList>\n            <Title>REFERENCES</Title>\n            <Reference>\n                <Citation>Garzon MC, Huang JT, Enjolras O, Frieden IJ. Vascular malformations: Part i. J Am Acad Dermatol 2007; 56: 353-370; quiz 371-354.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Legiehn GM, Heran MK. Venous malformations: Classification, development, diagnosis, and interventional radiologic management. Radiologic Clin North Am 2008; 46: 545-597.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Zhu JY, Ren JG, Zhang W et\xc2\xa0al. Characterization of microparticles in patients with venous malformations of the head and neck. Oral Dis 2017; 23: 110-119.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Behravesh S, Yakes W, Gupta N et\xc2\xa0al. Venous malformations: clinical diagnosis and treatment. Cardiovascular Diagnosis Therapy 2016; 6: 557-569.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Goines J, Li X, Cai Y et\xc2\xa0al. A xenograft model for venous malformation. Angiogenesis 2018; 21: 725-735.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Udan RS, Culver JC, Dickinson ME. Understanding vascular development. Wiley Interdisciplinary Reviews. Developmental Biology 2013; 2: 327-346.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>von Tell D, Armulik A, Betsholtz C. Pericytes and vascular stability. Experimental Cell Res 2006; 312: 623-629.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Moiseeva EP. Adhesion receptors of vascular smooth muscle cells and their functions. Cardiovascular Res 2001; 52: 372-386.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Davis GE, Senger DR. Endothelial extracellular matrix: Biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circulation Res 2005; 97: 1093-1107.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Chen G, Ren JG, Zhang W et\xc2\xa0al. Disorganized vascular structures in sporadic venous malformations: A possible correlation with balancing effect between tie2 and tgf-beta. Scientific Rep 2014; 4: 5457.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Kangas J, Natynki M, Eklund L. Development of molecular therapies for venous malformations. Basic Clin Pharmacol Toxicol 2018; 123(Suppl 5): 6-19.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Ren JG, Chen G, Zhu JY et\xc2\xa0al. Downregulation of the transforming growth factor-beta/connective tissue growth factor 2 signalling pathway in venous malformations: Its target potential for sclerotherapy. Br J Dermatol 2014; 171: 242-251.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Lucero HA, Kagan HM. Lysyl oxidase: An oxidative enzyme and effector of cell function. Cellular Molecular Life Sci 2006; 63: 2304-2316.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Rodriguez C, Martinez-Gonzalez J, Raposo B, Alcudia JF, Guadall A, Badimon L. Regulation of lysyl oxidase in vascular cells: Lysyl oxidase as a new player in cardiovascular diseases. Cardiovascular Res 2008; 79: 7-13.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Kobayashi H, Ishii M, Chanoki M et\xc2\xa0al. Immunohistochemical localization of lysyl oxidase in normal human skin. Br J Dermatol 1994; 131: 325-330.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Maki JM. Lysyl oxidases in mammalian development and certain pathological conditions. Histol Histopathol 2009; 24: 651-660.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Afratis NA, Klepfish M, Karamanos NK, Sagi I. The apparent competitive action of ECM proteases and cross-linking enzymes during fibrosis: Applications to drug discovery. Adv Drug Deliv Rev 2018; 129: 4-15.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Wang TH, Hsia SM, Shieh TM. Lysyl oxidase and the tumor microenvironment. Int J Mol Sci 2017; 18: 62.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Zhu JY, Zhang W, Ren JG, Chen G, Zhao YF. Characterization of endothelial microparticles induced by different therapeutic drugs for infantile hemangioma. J Cardiovascular Pharmacol 2015; 66: 261-269.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Palamakumbura AH, Trackman PC. A fluorometric assay for detection of lysyl oxidase enzyme activity in biological samples. Anal Biochem 2002; 300: 245-251.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Ribatti D, Nico B, Crivellato E. Morphological and molecular aspects of physiological vascular morphogenesis. Angiogenesis 2009; 12: 101-111.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Vikkula M, Boon LM, Carraway KL 3rd et\xc2\xa0al. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase tie2. Cell 1996; 87: 1181-1190.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Xia HF, Ren JG, Zhu JY et\xc2\xa0al. Downregulation of mir-145 in venous malformations: Its association with disorganized vessels and sclerotherapy. Eur J Pharmaceut Sci 2017; 100: 126-131.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Hultgardh-Nilsson A, Durbeej M. Role of the extracellular matrix and its receptors in smooth muscle cell function: Implications in vascular development and disease. Curr Opin Lipidol 2007; 18: 540-545.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Brooke BS, Karnik SK, Li DY. Extracellular matrix in vascular morphogenesis and disease: Structure versus signal. Trends Cell Biol 2003; 13: 51-56.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Suzuki S, Narita Y, Yamawaki A et\xc2\xa0al. Effects of extracellular matrix on differentiation of human bone marrow-derived mesenchymal stem cells into smooth muscle cell lineage: Utility for cardiovascular tissue engineering. Cells, Tissues, Organs 2010; 191: 269-280.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Limaye N, Kangas J, Mendola A et\xc2\xa0al. Somatic activating pik3ca mutations cause venous malformation. Am J Human Genet 2015; 97: 914-921.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Maki JM, Rasanen J, Tikkanen H et\xc2\xa0al. Inactivation of the lysyl oxidase gene lox leads to aortic aneurysms, cardiovascular dysfunction, and perinatal death in mice. Circulation 2002; 106: 2503-2509.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Fang Y, Chang HM, Cheng JC, Klausen C, Leung PC, Yang X. Transforming growth factor-beta1 increases lysyl oxidase expression by downregulating mir29a in human granulosa lutein cells. Reproduction 2016; 152: 205-213.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Gacheru SN, Thomas KM, Murray SA, Csiszar K, Smith-Mungo LI, Kagan HM. Transcriptional and post-transcriptional control of lysyl oxidase expression in vascular smooth muscle cells: Effects of tgf-beta 1 and serum deprivation. J Cellular Biochem 1997; 65: 395-407.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Feres-Filho EJ, Choi YJ, Han X, Takala TE, Trackman PC. Pre- and post-translational regulation of lysyl oxidase by transforming growth factor-beta 1 in osteoblastic mc3t3-e1 cells. J Biol Chem 1995; 270: 30797-30803.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Voloshenyuk TG, Landesman ES, Khoutorova E, Hart AD, Gardner JD. Induction of cardiac fibroblast lysyl oxidase by tgf-beta1 requires pi3k/akt, smad3, and mapk signaling. Cytokine 2011; 55: 90-97.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Leask A, Abraham DJ. Tgf-beta signaling and the fibrotic response. FASEB J 2004; 18: 816-827.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Natynki M, Kangas J, Miinalainen I et\xc2\xa0al. Common and specific effects of tie2 mutations causing venous malformations. Human Mol Genet 2015; 24: 6374-6389.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Boscolo E, Limaye N, Huang L et\xc2\xa0al. Rapamycin improves tie2-mutated venous malformation in murine model and human subjects. J Clin Invest 2015; 125: 3491-3504.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Zhang W, Chen G, Ren JG, Zhao YF. Bleomycin induces endothelial mesenchymal transition through activation of mtor pathway: A possible mechanism contributing to the sclerotherapy of venous malformations. Br J Pharmacol 2013; 170: 1210-1220.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Fowell C, Verea Linares C, Jones R, Nishikawa H, Monaghan A. Venous malformations of the head and neck: current concepts in management. Br J Oral Maxillofacial Surgery 2017; 55: 3-9.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Hashimoto N, Phan SH, Imaizumi K et\xc2\xa0al. Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. Am J Respiratory Cell Mol Biol 2010; 43: 161-172.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Li S, Yang X, Li W et\xc2\xa0al. N-acetylcysteine downregulation of lysyl oxidase activity alleviating bleomycin-induced pulmonary fibrosis in rats. Respiration 2012; 84: 509-517.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Cheng T, Liu Q, Zhang R et\xc2\xa0al. Lysyl oxidase promotes bleomycin-induced lung fibrosis through modulating inflammation. J Mol Cell Biol 2014; 6: 506-515.</Citation>\n            </Reference>\n        </ReferenceList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'